These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 30824647)

  • 21. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies.
    Radominski SC; Cardiel MH; Citera G; Goecke A; Jaller JJ; Lomonte ABV; Miranda P; Velez P; Xibillé D; Kwok K; Rojo R; García EG
    Reumatol Clin; 2017; 13(4):201-209. PubMed ID: 27317492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis.
    Strand V; van Vollenhoven RF; Lee EB; Fleischmann R; Zwillich SH; Gruben D; Koncz T; Wilkinson B; Wallenstein G
    Rheumatology (Oxford); 2016 Jun; 55(6):1031-41. PubMed ID: 26929445
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy.
    Takeuchi T; Fleischmann R; Iikuni N; Shi H; Soma K; Paulissen J; Hirose T; Smolen JS
    Arthritis Res Ther; 2021 Aug; 23(1):220. PubMed ID: 34429160
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study.
    van der Heijde D; Strand V; Tanaka Y; Keystone E; Kremer J; Zerbini CAF; Cardiel MH; Cohen S; Nash P; Song YW; Tegzová D; Gruben D; Wallenstein G; Connell CA; Fleischmann R;
    Arthritis Rheumatol; 2019 Jun; 71(6):878-891. PubMed ID: 30666826
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial.
    Mease P; Husni ME; Kafka S; Chakravarty SD; Harrison DD; Lo KH; Xu S; Hsia EC; Kavanaugh A
    Arthritis Res Ther; 2020 Mar; 22(1):43. PubMed ID: 32143685
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tofacitinib for the treatment of psoriasis and psoriatic arthritis.
    Berekmeri A; Mahmood F; Wittmann M; Helliwell P
    Expert Rev Clin Immunol; 2018 Sep; 14(9):719-730. PubMed ID: 30118353
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.
    Kremer J; Li ZG; Hall S; Fleischmann R; Genovese M; Martin-Mola E; Isaacs JD; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Riese R; Bradley J
    Ann Intern Med; 2013 Aug; 159(4):253-61. PubMed ID: 24026258
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tofacitinib versus methotrexate in rheumatoid arthritis.
    Lee EB; Fleischmann R; Hall S; Wilkinson B; Bradley JD; Gruben D; Koncz T; Krishnaswami S; Wallenstein GV; Zang C; Zwillich SH; van Vollenhoven RF;
    N Engl J Med; 2014 Jun; 370(25):2377-86. PubMed ID: 24941177
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial.
    Ritchlin CT; Coates LC; Mease PJ; van der Heijde D; Song J; Jiang Y; Shawi M; Kollmeier AP; Rahman P
    Trials; 2023 Jan; 24(1):22. PubMed ID: 36627711
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol.
    van der Heijde D; Fleischmann R; Wollenhaupt J; Deodhar A; Kielar D; Woltering F; Stach C; Hoepken B; Arledge T; Mease PJ
    Ann Rheum Dis; 2014 Jan; 73(1):233-7. PubMed ID: 23942869
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs.
    Fleischmann R; Cutolo M; Genovese MC; Lee EB; Kanik KS; Sadis S; Connell CA; Gruben D; Krishnaswami S; Wallenstein G; Wilkinson BE; Zwillich SH
    Arthritis Rheum; 2012 Mar; 64(3):617-29. PubMed ID: 21952978
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.
    Gladman DD; Mease PJ; Ritchlin CT; Choy EH; Sharp JT; Ory PA; Perdok RJ; Sasso EH
    Arthritis Rheum; 2007 Feb; 56(2):476-88. PubMed ID: 17265483
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis: a cost-effectiveness analysis compared with adalimumab in Taiwan.
    Chen DY; Hsu PN; Tang CH; Claxton L; Valluri S; Gerber RA
    J Med Econ; 2019 Aug; 22(8):777-787. PubMed ID: 30982378
    [No Abstract]   [Full Text] [Related]  

  • 34. Evaluation of disease activity in patients with rheumatoid arthritis treated with tofacitinib by RAPID3: post hoc analyses from two phase 3 trials.
    Strand V; Lee EB; Yazici Y; Dikranian A; Wilkinson B; Takiya L; Zang C; Bananis E; Bergman MJ
    Clin Rheumatol; 2018 Aug; 37(8):2043-2053. PubMed ID: 29656373
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies.
    Nash P; Coates LC; Fleischmann R; Papp KA; Gomez-Reino JJ; Kanik KS; Wang C; Wu J; Menon S; Hendrikx T; Ports WC
    Rheumatol Ther; 2018 Dec; 5(2):567-582. PubMed ID: 30414064
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials.
    Kavanaugh A; Ritchlin C; Rahman P; Puig L; Gottlieb AB; Li S; Wang Y; Noonan L; Brodmerkel C; Song M; Mendelsohn AM; McInnes IB;
    Ann Rheum Dis; 2014 Jun; 73(6):1000-6. PubMed ID: 24553909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tofacitinib prevents radiographic progression in rheumatoid arthritis.
    Kim JW; Choi IA; Lee EY; Song YW; Lee EB
    J Korean Med Sci; 2013 Aug; 28(8):1134-8. PubMed ID: 23960438
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2.
    van der Heijde D; Kavanaugh A; Gladman DD; Antoni C; Krueger GG; Guzzo C; Zhou B; Dooley LT; de Vlam K; Geusens P; Birbara C; Halter D; Beutler A
    Arthritis Rheum; 2007 Aug; 56(8):2698-707. PubMed ID: 17665424
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group.
    Fleischmann R; Mease PJ; Schwartzman S; Hwang LJ; Soma K; Connell CA; Takiya L; Bananis E
    Clin Rheumatol; 2017 Jan; 36(1):15-24. PubMed ID: 27734232
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study.
    van der Heijde D; Tanaka Y; Fleischmann R; Keystone E; Kremer J; Zerbini C; Cardiel MH; Cohen S; Nash P; Song YW; Tegzová D; Wyman BT; Gruben D; Benda B; Wallenstein G; Krishnaswami S; Zwillich SH; Bradley JD; Connell CA;
    Arthritis Rheum; 2013 Mar; 65(3):559-70. PubMed ID: 23348607
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.